company background image
BD1

BARD1 Life SciencesASX:BD1 Stock Report

Market Cap

AU$100.7m

7D

-0.9%

1Y

40.4%

Updated

21 Oct, 2021

Data

Company Financials
BD1 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BD1 Overview

BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia.

BARD1 Life Sciences Competitors

BCAL Diagnostics

ASX:BDX

AU$34.1m

Price History & Performance

Summary of all time highs, changes and price drops for BARD1 Life Sciences
Historical stock prices
Current Share PriceAU$1.10
52 Week HighAU$0.57
52 Week LowAU$5.60
Beta-0.64
1 Month Change-6.41%
3 Month Change-35.40%
1 Year Change40.39%
3 Year Change4.29%
5 Year Change4.29%
Change since IPO52.08%

Recent News & Updates

Shareholder Returns

BD1AU HealthcareAU Market
7D-0.9%1.1%0.7%
1Y40.4%13.1%21.4%

Return vs Industry: BD1 exceeded the Australian Healthcare industry which returned 10.7% over the past year.

Return vs Market: BD1 exceeded the Australian Market which returned 21.1% over the past year.

Price Volatility

Is BD1's price volatile compared to industry and market?
BD1 volatility
BD1 Beta-0.64
Industry Beta0.60
Market Beta1

Stable Share Price: BD1 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BD1's weekly volatility has decreased from 25% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198315Leearne Hinchhttps://www.bard1.com

BARD1 Life Sciences Limited engages in the research, development, and commercialization of diagnostic products for the early detection of cancer to enhance patient outcomes in Australia. The company offers hTERT test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for ovarian and breast cancers, and research-stage projects for prostate and other cancers.

BARD1 Life Sciences Fundamentals Summary

How do BARD1 Life Sciences's earnings and revenue compare to its market cap?
BD1 fundamental statistics
Market CapAU$100.67m
Earnings (TTM)-AU$11.15m
Revenue (TTM)AU$1.27m

79.2x

P/S Ratio

-9.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BD1 income statement (TTM)
RevenueAU$1.27m
Cost of RevenueAU$1.77m
Gross Profit-AU$499.41k
ExpensesAU$10.65m
Earnings-AU$11.15m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.12
Gross Margin-39.30%
Net Profit Margin-877.49%
Debt/Equity Ratio0%

How did BD1 perform over the long term?

See historical performance and comparison

Valuation

Is BARD1 Life Sciences undervalued compared to its fair value and its price relative to the market?

3.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BD1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.

PE vs Market: BD1 is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BD1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BD1 is overvalued based on its PB Ratio (3.5x) compared to the AU Healthcare industry average (2.2x).


Future Growth

How is BARD1 Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

1.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BARD1 Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has BARD1 Life Sciences performed over the past 5 years?

-25.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BD1 is currently unprofitable.

Growing Profit Margin: BD1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BD1 is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.

Accelerating Growth: Unable to compare BD1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BD1 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).


Return on Equity

High ROE: BD1 has a negative Return on Equity (-38.38%), as it is currently unprofitable.


Financial Health

How is BARD1 Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: BD1's short term assets (A$5.6M) exceed its short term liabilities (A$1.5M).

Long Term Liabilities: BD1's short term assets (A$5.6M) exceed its long term liabilities (A$3.0M).


Debt to Equity History and Analysis

Debt Level: BD1 is debt free.

Reducing Debt: BD1 has no debt compared to 5 years ago when its debt to equity ratio was 2.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BD1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BD1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.7% each year


Dividend

What is BARD1 Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BD1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BD1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BD1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BD1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BD1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Leearne Hinch

4.92yrs

Tenure

AU$867,287

Compensation

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of BARD1 Life Sciences Limited since November 7, 2016. Dr. Hinch is a biotechnology executive and consultant...


CEO Compensation Analysis

Compensation vs Market: Leearne's total compensation ($USD649.51K) is above average for companies of similar size in the Australian market ($USD303.55K).

Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BD1's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: BD1's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.


Top Shareholders

Company Information

BARD1 Life Sciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: BARD1 Life Sciences Limited
  • Ticker: BD1
  • Exchange: ASX
  • Founded: 1983
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$100.669m
  • Shares outstanding: 91.93m
  • Website: https://www.bard1.com

Number of Employees


Location

  • BARD1 Life Sciences Limited
  • 23 Normanby Road
  • Notting Hill
  • Victoria
  • 3168
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:20
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.